Funai Kazuhito, Suzuki Kazuya, Sekihara Keigo, Shimizu Kei, Shiiya Norihiko
First Department of Surgery, Hamamatsu University School of Medicine, 1-20-1, Handayama, Higashi, Hamamatsu, Shizuoka 431-3192, Japan.
Gen Thorac Cardiovasc Surg. 2012 Jun;60(6):370-2. doi: 10.1007/s11748-012-0007-5. Epub 2012 May 12.
Several recent studies have demonstrated that some patients might benefit from aggressive therapy for thoracic stage I lung cancer and synchronous solitary brain metastasis. However, the indication for the patients with advanced T-stage is still unclear. We herein present a patient with synchronous solitary brain metastasis from non-small cell lung cancer who survived without recurrence for 5 years following surgery after chemotherapy, even though the primary tumor was T3N0 thoracic stage II. Aggressive treatment for both the primary site and brain metastasis may therefore be an effective treatment for locally advanced non-small cell lung cancer patients with synchronous solitary brain metastasis.
最近的几项研究表明，一些胸段I期肺癌合并同步孤立性脑转移的患者可能从积极治疗中获益。然而，T分期较晚患者的治疗指征仍不明确。我们在此报告1例非小细胞肺癌合并同步孤立性脑转移的患者，尽管其原发肿瘤为胸段II期T3N0，但在化疗后接受手术治疗，5年无复发存活。因此，对原发部位和脑转移灶均进行积极治疗，可能是治疗局部晚期非小细胞肺癌合并同步孤立性脑转移患者的有效方法。
